CO2023013445A2 - Forma cristalina de un compuesto de óxido de nitrógeno de piridina y uso de la misma - Google Patents
Forma cristalina de un compuesto de óxido de nitrógeno de piridina y uso de la mismaInfo
- Publication number
- CO2023013445A2 CO2023013445A2 CONC2023/0013445A CO2023013445A CO2023013445A2 CO 2023013445 A2 CO2023013445 A2 CO 2023013445A2 CO 2023013445 A CO2023013445 A CO 2023013445A CO 2023013445 A2 CO2023013445 A2 CO 2023013445A2
- Authority
- CO
- Colombia
- Prior art keywords
- nitrogen oxide
- oxide compound
- crystal form
- pyridine nitrogen
- crystalline form
- Prior art date
Links
- -1 pyridine nitrogen oxide compound Chemical class 0.000 title abstract 2
- 239000013078 crystal Substances 0.000 title 1
- 150000001875 compounds Chemical class 0.000 abstract 1
- 239000008194 pharmaceutical composition Substances 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
- C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
- C07D213/89—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members with hetero atoms directly attached to the ring nitrogen atom
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4425—Pyridinium derivatives, e.g. pralidoxime, pyridostigmine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/14—Antitussive agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/04—Centrally acting analgesics, e.g. opioids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
- C07B2200/00—Indexing scheme relating to specific properties of organic compounds
- C07B2200/13—Crystalline forms, e.g. polymorphs
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Epidemiology (AREA)
- Pain & Pain Management (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Rheumatology (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Pulmonology (AREA)
- Pyridine Compounds (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
Un forma cristalina de un compuesto de óxido de nitrógeno de piridina y el uso de la misma. Específicamente, la presente invención se refiere a una forma cristalina de un compuesto de fórmula (I), una composición farmacéutica y un uso de la misma.
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN202110265997 | 2021-03-11 | ||
CN202210195905 | 2022-03-01 | ||
PCT/CN2022/080430 WO2022188872A1 (zh) | 2021-03-11 | 2022-03-11 | 吡啶氮氧化合物晶型及其应用 |
Publications (1)
Publication Number | Publication Date |
---|---|
CO2023013445A2 true CO2023013445A2 (es) | 2024-02-15 |
Family
ID=83226280
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CONC2023/0013445A CO2023013445A2 (es) | 2021-03-11 | 2023-10-10 | Forma cristalina de un compuesto de óxido de nitrógeno de piridina y uso de la misma |
Country Status (13)
Country | Link |
---|---|
US (1) | US20240208908A1 (es) |
EP (1) | EP4306511A1 (es) |
JP (1) | JP2024509939A (es) |
KR (1) | KR20240019064A (es) |
CN (1) | CN116829539A (es) |
AU (1) | AU2022233221A1 (es) |
BR (1) | BR112023018348A2 (es) |
CA (1) | CA3211594A1 (es) |
CL (1) | CL2023002687A1 (es) |
CO (1) | CO2023013445A2 (es) |
MX (1) | MX2023010704A (es) |
TW (1) | TW202300147A (es) |
WO (1) | WO2022188872A1 (es) |
Families Citing this family (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN116891432A (zh) * | 2022-04-02 | 2023-10-17 | 武汉人福创新药物研发中心有限公司 | Nav1.8抑制剂及其用途 |
TW202348229A (zh) * | 2022-06-02 | 2023-12-16 | 大陸商上海濟煜醫藥科技有限公司 | 吡啶氮氧化合物的製備方法 |
CN117263856A (zh) * | 2022-06-22 | 2023-12-22 | 武汉人福创新药物研发中心有限公司 | Nav1.8抑制剂 |
Family Cites Families (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
TW201920081A (zh) | 2017-07-11 | 2019-06-01 | 美商維泰克斯製藥公司 | 作為鈉通道調節劑的羧醯胺 |
CA3105657A1 (en) * | 2018-07-09 | 2020-01-16 | Lieber Institute, Inc. | Pyridine carboxamide compounds for inhibiting nav1.8 |
PE20221515A1 (es) * | 2019-09-12 | 2022-10-04 | Shanghai Jemincare Pharmaceuticals Co Ltd | Oxinitruro de piridina, metodo para su preparacion y uso de este |
CN112225695B (zh) * | 2020-12-15 | 2021-03-02 | 上海济煜医药科技有限公司 | 一种氮氧化合物及其制备方法和用途 |
-
2022
- 2022-03-11 TW TW111109094A patent/TW202300147A/zh unknown
- 2022-03-11 EP EP22766394.5A patent/EP4306511A1/en active Pending
- 2022-03-11 BR BR112023018348A patent/BR112023018348A2/pt unknown
- 2022-03-11 MX MX2023010704A patent/MX2023010704A/es unknown
- 2022-03-11 JP JP2023555355A patent/JP2024509939A/ja active Pending
- 2022-03-11 AU AU2022233221A patent/AU2022233221A1/en active Pending
- 2022-03-11 WO PCT/CN2022/080430 patent/WO2022188872A1/zh active Application Filing
- 2022-03-11 US US18/549,984 patent/US20240208908A1/en active Pending
- 2022-03-11 KR KR1020237034827A patent/KR20240019064A/ko unknown
- 2022-03-11 CN CN202280013148.1A patent/CN116829539A/zh active Pending
- 2022-03-11 CA CA3211594A patent/CA3211594A1/en active Pending
-
2023
- 2023-09-08 CL CL2023002687A patent/CL2023002687A1/es unknown
- 2023-10-10 CO CONC2023/0013445A patent/CO2023013445A2/es unknown
Also Published As
Publication number | Publication date |
---|---|
CL2023002687A1 (es) | 2024-03-08 |
MX2023010704A (es) | 2023-12-07 |
AU2022233221A1 (en) | 2023-10-26 |
KR20240019064A (ko) | 2024-02-14 |
TW202300147A (zh) | 2023-01-01 |
JP2024509939A (ja) | 2024-03-05 |
CA3211594A1 (en) | 2022-09-15 |
BR112023018348A2 (pt) | 2023-12-05 |
CN116829539A (zh) | 2023-09-29 |
EP4306511A1 (en) | 2024-01-17 |
WO2022188872A1 (zh) | 2022-09-15 |
US20240208908A1 (en) | 2024-06-27 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CO2023013445A2 (es) | Forma cristalina de un compuesto de óxido de nitrógeno de piridina y uso de la misma | |
CY1122585T1 (el) | Συνδυασμοι που περιλαμβανουν παραγωγα 5-φαινοξυ-3η-πυριμιδιν-4-ονης και η χρηση αυτων για την προφυλαξη ή αγωγη λοιμωξης απο ηiv | |
CL2019000477A1 (es) | Un esteroide 19 nor-c21-n-pirazolilo c3,3- disustituido cristalino. | |
AR107864A1 (es) | ÁCIDO 7a,11b-DIHIDROXI-6a-ETIL-5b-COLAN-24-OICO Y COMPOSICIONES FARMACÉUTICAS | |
CR20190423A (es) | Nuevos compuestos biciclícos como inhibidores dobles de atx/ca | |
EA200500203A1 (ru) | Новый способ синтеза и новая кристаллическая форма агомелатина и фармацевтические композиции, которые её содержат | |
PH12016500072B1 (en) | Piperidinyl-indole derivatives complement factor b inhibitors and uses thereof | |
CY1123689T1 (el) | Κρυσταλλικη μορφη ελευθερης βασης λορλατινιβης | |
AR084032A1 (es) | Compuesto biciclico | |
CR20170605A (es) | DERIVADOS DE 3-TETRAZOLIL-BENCENO-1,2-DISULFONAMIDA COMO INHIBIDORES DE METALO -ß-LACTAMASA | |
ECSP11010878A (es) | Formas cristalinas de un derivado de 2-tiazolil-4-quinolinil-oxi, un potente inhibidor de hcv. | |
UY32490A (es) | Inhibidores de beta-secretasa | |
NO20080761L (no) | Acykliske Ikur inhibitorer | |
SV2008003088A (es) | Nueva forma cristalina vi de la agomelatina, su procedimiento de preparacion y las composiciones farmaceuticas que la contienen | |
MX2016000675A (es) | Derivados de amino-metil-biarilo como inhibidores del factor de complemento d y usos de los mismos. | |
NI201200146A (es) | Inhibidores no nucleosídicos de la transcriptasa inversa | |
CL2018002089A1 (es) | Maleato de agonista de tlr7, sus formas cristalinas c, d y e, sus procesos de preparación y su uso | |
CO6300946A2 (es) | Forma cristalina de derivado de fenilamino pirimidina | |
ECSP23002606A (es) | Nuevo inhibidor de la secreción de ácido y uso del mismo | |
ECSP109919A (es) | Compuesto de piridacina cristalina | |
PH12015501752B1 (en) | Substituted bisphenyl butanoic phosphonic acid derivatives as nep inhibitors | |
CL2021000421A1 (es) | Nuevo derivado de amina heterocíclico y composición farmacéutica que lo comprende. | |
CO2022010011A2 (es) | Derivado de amino arilo novedoso útil como inhibidor de diacilglicerol aciltransferasa 2 y uso del mismo | |
CO2024004552A2 (es) | Compuestos heteroarilo bicíclicos fusionados útiles como inhibidores de nlrp3 | |
PE20211756A1 (es) | FORMAS POLIMORFICAS NOVEDOSAS DE UN INHIBIDOR DE TGFß |